AI can design drugs.
It still can't predict people.
Quris spent six years
building BioAI to close that gap.
The world is entering a global AI race to transform drug development. Quris built BioAI: one integrated engine combining AI with patient-specific 3D human biology to generate and learn from predictive human-response data. Governments, regulators, pharma and AI leaders are now converging around the infrastructure Quris began building six years ago.
Drugs are one-size-fits-all.
People are not.
Drug development still discovers human differences too late.
A drug—or dose—that helps one patient may harm another. Those differences are usually found late, in the clinic, and roughly nine in ten drug candidates that enter clinical testing still fail. Neither conventional biology nor AI trained on existing literature could solve this alone. The missing capability was a system able to generate new human data—and learn to predict from it.
AI and 3D human biology can now work as one.
The result is a new predictive infrastructure: BioAI.
AI is producing drug candidates faster, while patient-specific 3D organ models can generate human-response data that previously did not exist. Regulation is opening pathways for human-relevant evidence, and pharma is investing billions in vertical AI. The convergence is BioAI: living experiments and machine learning operating as one system.
BioAI: Integrating AI
with BioAvatars
Quris integrates patient-specific BioAvatars, automated experiments, molecular analysis and AI in one continuous loop.
Known drugs generate human-response data; that data trains BioAI; BioAI predicts the safety of new drugs. Every experiment expands Quris’ proprietary dataset and strengthens the same integrated engine.
Integrated BioAI wins.
Validated with Merck and other top pharma.
In blinded prospective studies with Merck and other leading pharmaceutical companies, Quris BioAI outperformed both AI-only and biology-only approaches. In one program it flagged a rare liver-toxicity risk months before that risk was seen clinically. Pharma customers have expanded their engagements, with Quris retaining 100% of its pharma customers. Explore validation ›
“Quris flags drug toxicity that all our models completely missed.”
The people behind Quris
changed industries before.
Now they are helping build the BioAI category.
Quris brings together leadership and advisors spanning Nobel-winning science, the creation of Moderna, global pharma, medtech, AI and company building—the rare combination required to turn a new scientific capability into a category-defining business. Meet the team ›
Human prediction can change the economics of drug development.
From pre-IND safety through late-stage clinical evidence.
Quris’ validated capability today is drug-safety evaluation in functional human liver models. Population personalization, patient stratification, dose optimization and trial design are a development roadmap, not validated clinical products.
The validated platform is the entry point—not the destination. As regulators open pathways for human-relevant evidence, avoiding even one unnecessary Phase 3 trial—often $30–100M—could transform a program’s timeline, economics and value.
One BioAI engine.
Three expanding opportunities.
Validated safety. Population personalization. Accelerated development.
Each application runs on—and adds learning back to—the same BioAI platform. Drug-safety programs generate proprietary human data. Population deployments expand its biological diversity. Accelerated drug development applies that intelligence to larger clinical and portfolio decisions. Beyond pharma, the engine creates further optionality in sovereign BioAI, therapeutics and longevity. Explore BioAI ›
The world is moving toward BioAI.
Quris has already built it.
Six years integrating 3D human biology with AI. Validated with top pharma. Expanding into the largest decisions in drug development.